“Great Advances in Oncology” – Episode 2/4. Discovered more than three decades ago at Gustave Roussy, the LAG‑3 gene is now at the heart of the development of new anticancer treatments. By targeting it, scientists aim to remove one of the brakes that can limit the immune system’s ability to fight cancer cells. 

Inserm – the French National Institute of Health and Medical Research – is the only French public research organisation entirely dedicated to human health. Each year, its new tenured research fellows are recruited through a highly selective competitive process. For the 2026 edition, five young researchers from Gustave Roussy are among the awardees...

"Great Advances in Oncology” – Episode 1/4. Developed in the 1940s by Professor Pierre Denoix, the TNM classification has gradually become the tool that enables oncologists worldwide to determine the stage of their patients’ cancer within a unified framework. Still in use today, it reached its 9th edition in 2025.

The Cancer Research Institute (CRI) has awarded the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology to Prof. Éric Vivier, holder of the Natural Killer (NK) Cell Chair of the Fondation Gustave Roussy. This distinction, one of the most prestigious in cancer immunology, recognizes his body of work, which has profoundly...

From 17 to 19 June in Paris, the IFODS Congress, a benchmark event for French-speaking oncology, will highlight the latest advances in the global fight against cancer, with insights from leading experts. On Thursday, 18 June, an IFODS/Gustave Roussy presidential session will take stock of key topics in oncology. On the programme: therapeutic...

Du 13 au 23 juin 2026, le Groupe TF1 lance la quatrième édition de « Mobilisation Cancer, tous ensemble avec les chercheurs », en partenariat avec Gustave Roussy et la Fondation ARC. Après une édition 2025 qui a permis de collecter près de 885 000 euros, l’ambition est d’accélérer cet élan de solidarité.